首页|Multi-omics joint analysis revealed the metabolic profile of retroperitoneal liposarcoma

Multi-omics joint analysis revealed the metabolic profile of retroperitoneal liposarcoma

扫码查看
Retroperitoneal liposarcoma(RLPS)is the main subtype of retroperitoneal soft sarcoma(RSTS)and has a poor prognosis and few treatment options,except for surgery.The proteomic and metabolic profiles of RLPS have remained unclear.The aim of our study was to reveal the metabolic profile of RLPS.Here,we performed proteomic analysis(n=10),metabolomic analysis(n=51),and lipidomic analysis(n=50)of retroperitoneal dedifferentiated liposarcoma(RDDLPS)and retroperitoneal well-differentiated liposarcoma(RWDLPS)tissue and paired adjacent adipose tissue obtained during surgery.Data analysis mainly revealed that glycolysis,purine metabolism,pyrimidine metabolism and phospholipid formation were upregulated in both RDDLPS and RWDLPS tissue compared with the adjacent adipose tissue,whereas the tricarboxylic acid(TCA)cycle,lipid absorption and synthesis,fatty acid degradation and biosynthesis,as well as glycine,serine,and threonine metabolism were downregulated.Of particular importance,the glycolytic inhibitor 2-deoxy-D-glucose and pentose phosphate pathway(PPP)inhibitor RRX-001 significantly promoted the antitumor effects of the MDM2 inhibitor RG7112 and CDK4 inhibitor abemaciclib.Our study not only describes the metabolic profiles of RDDLPS and RWDLPS,but also offers potential therapeutic targets and strategies for RLPS.

RLPSproteomicsmetabolomicslipidomicsmetabolism

Fu'an Xie、Yujia Niu、Lanlan Lian、Yue Wang、Aobo Zhuang、Guangting Yan、Yantao Ren、Xiaobing Chen、Mengmeng Xiao、Xi Li、Zhe Xi、Gen Zhang、Dongmei Qin、Kunrong Yang、Zhigang Zheng、Quan Zhang、Xiaogang Xia、Peng Li、Lingwei Gu、Ting Wu、Chenghua Luo、Shu-Hai Lin、Wengang Li

展开 >

iCancer Research Center,Xiang'an Hospital of Xiamen University,School of Medicine,Xiamen University,Xiamen 361102,China

State Key Laboratory of Cellular Stress Biology,School of Life Sciences,Faculty of Medicine and Life Sciences,Xiamen University,Xiamen 361102,China

Xiamen University Research Center of Retroperitoneal Tumor Committee of Oncology Society of Chinese Medical Association,Xiamen University,Xiamen 361102,China

Department of Laboratory Medicine,Xiang,an Hospital of Xiamen University,School of Medicine,Xiamen University,Xiamen 361102,China

Department of Retroperitoneal Tumor Surgery,Peking University International Hospital,Beijing 102206,China

School of Public Health,Harvard University,Boston,MA 02115,USA

Cancer Research Center,Xiang'an Hospital of Xiamen University,School of Medicine,Xiamen University,Xiamen 361102,China

Laboratory of Biochemistry and Molecular Biology Research,Department of Clinical Laboratory,Fujian Medical University Cancer Hospital,Fuzhou 350014,China

Surgery Department,Affiliated Fuzhou First Hospital of Fujian Medical University,Fuzhou 350009,China

National Institute for Data Science in Health and Medicine,Xiamen University,Xiamen 361102,China

Department of Hepatobiliary Surgery,Xiang'an Hospital of Xiamen University,School of Medicine,Xiamen University,Xiamen 361102,China

Department of Hepatobiliary Surgery,Xiang'an Hospital of Xiamen University,School of Me

展开 >

国家自然科学基金国家自然科学基金国家自然科学基金Scientific Research Foundation for Advanced Talents,Xiang'an Hospital of Xiamen UniversityJoint laboratory of School of Medicine,Xiamen University-Shanghai Jiangxia Blood Technology Co.Ltd中央高校基本科研业务费专项Major Science and Technology Special Project of Fujian Province福建省自然科学基金

822729359195712021974114PM20180917008XDHT2020010C207202100012022YZ0360122021J01123522

2024

医学前沿
高等教育出版社

医学前沿

CSTPCD
影响因子:1.362
ISSN:2095-0217
年,卷(期):2024.18(2)
  • 1
  • 31